Mochida Pharmaceutical
4534.T4534.T · Stock Price
Historical price data
Overview
Mochida Pharmaceutical is a mission-driven company focused on contributing to human health through the creation of innovative pharmaceuticals. It has achieved a dominant position in the Japanese market with a diversified portfolio and a robust, fully integrated operational model. Its core strategy balances the steady cash flows from its consumer healthcare and diagnostic businesses with targeted R&D investments in novel prescription drugs, supplemented by strategic global partnerships to access new technologies and markets. With a market capitalization of $127.8 billion, it represents a cornerstone of stability and long-term value in the biopharmaceutical sector.
Technology Platform
Mochida's core technology strength is its broad-based, integrated pharmaceutical science expertise in medicinal chemistry, advanced formulation/drug delivery, and diagnostics development, rather than a single proprietary platform.
Pipeline
15| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) | Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease | Approved | |
| FYU-981 + Febuxostat | Hyperuricemia With or Without Gout | Phase 3 | |
| FYU-981 | Hyperuricemia With or Without Gout | Phase 3 | |
| Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300) | Hypertriglyceridemia | Phase 3 | |
| Enbrel + LBEC0101 | Arthritis, Rheumatoid | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
Mochida competes domestically with Japanese pharma giants like Takeda and Daiichi Sankyo, and globally with large biopharma in oncology/immunology. Its integrated model, financial stability, and strong OTC/diagnostics base provide differentiation against pure-play R&D biotechs.